MARKET

AMRS

AMRS

Amyris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
+0.200
+7.02%
After Hours: 3.000 -0.05 -1.65% 17:15 10/23 EDT
OPEN
2.900
PREV CLOSE
2.850
HIGH
3.060
LOW
2.855
VOLUME
2.23M
TURNOVER
--
52 WEEK HIGH
6.07
52 WEEK LOW
1.400
MARKET CAP
624.43M
P/E (TTM)
-1.3844
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Amyris To Host Third Quarter 2020 Financial Results Conference Call On November 5
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it will issue its financial results for the fiscal 2020 third quarter ended September
PR Newswire · 12h ago
Amyris in licensing pact with IDRI on RNA vaccine platform
Amyris (AMRS) climbs 3% in premarket on light volume, after it signed a collaboration and license agreement with the Infectious Disease Research Institute ((IDRI)) to advance a novel ribonucleic acid vaccine platform,
Seekingalpha · 1d ago
Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.
PR Newswire · 1d ago
Amyris And The Infectious Disease Research Institute Enter Into Exclusive License For Novel RNA Vaccine Platform, Beginning With COVID-19 Vaccine
EMERYVILLE, Calif., Oct. 22, 2020 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of
Benzinga · 1d ago
Amyris and Arzeda ink development collaboration agreement
Arzeda, the Protein Design company, entered into a joint development agreement with Amyris ([[AMRS]] -0.7%) to leverage the complementary nature of the two companies' technology platforms and thus accelerate the development and
Seekingalpha · 3d ago
Arzeda Reports Development Collaboration Deal With Amyris, No Terms Disclosed
Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the complementary nature of the two companies' technology
Benzinga · 3d ago
Amyris and Arzeda Enter into Development Collaboration Agreement
Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the complementary nature of the two companies' technology platforms to accelerate the development and commercialization of high value ingredients. This marks the second joint project between the parties. Amyris and Arzeda collaborated successfully on a Defense Advanced Research Projects Agency (DARPA) Technology Investment Agreement (TIA) during the period of 2015 – 2019.
PR Newswire · 3d ago
Amyris Says Co Delivering Sustainable Alternative To Shark Squalene Adjuvant 'Enabling Vaccines For All With No Sharks Killed'
Amyris Delivering Sustainable Alternative To Shark Squalene Adjuvant - Enabling Vaccines For All With No Sharks Killed EMERYVILLE, Calif., Oct. 1, 2020 /PRNewswire/ --Amyris, Inc. (NASDAQ:AMRS), a leading
Benzinga · 10/01 12:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRS. Analyze the recent business situations of Amyris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRS stock price target is 10.00 with a high estimate of 11.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 78.17M
% Owned: 38.18%
Shares Outstanding: 204.73M
TypeInstitutionsShares
Increased
44
11.26M
New
43
21.50M
Decreased
22
3.12M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Commodity Chemicals
+0.54%
Chemicals
+0.45%
Key Executives
Chairman/Independent Director
Geoffrey Duyk
Chief Executive Officer/President/Director
John Melo
Corporate Executive
Oreste Fieschi
Chief Financial Officer
Han Kieftenbeld
Chief Operating Officer
Eduardo Alvarez
Chief Accounting Officer
Anthony Hughes
Chief Marketing Officer
Sheila Pollak
General Counsel/Secretary
Nicole Kelsey
Other
Kathleen Valiasek
Director
Philip Eykerman
Director
Christoph Goppelsroeder
Director
Julie Washington
Independent Director
John Doerr
Independent Director
Frank Kung
Independent Director
James McCann
Independent Director
Steven Mills
Independent Director
Carole Piwnica
Independent Director
Lisa Qi
Independent Director
Patrick Yang
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMRS
Amyris, Inc. is an industrial biotechnology company. The Company is primarily focused on applying its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor and Fragrance markets. Its technology platform enables users to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into volume, high-value ingredients. Its biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company’s platform is used to design, build, optimize and upscale strains producing eight distinct molecules at commercial volumes, to more than 15 commercial ingredients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Amyris Inc stock information, including NASDAQ:AMRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRS stock methods without spending real money on the virtual paper trading platform.